Display Settings:

Format

Send to:

Choose Destination

    Respir Res. 2001;2(3):164-8. Epub 2001 Apr 5.

    The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

    Somoskovi A, Parsons LM, Salfinger M.

    Wadsworth Center, New York State Department of Health, Albany, New York, USA.

    Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important antituberculosis drugs: isoniazid, rifampin, and pyrazinamide. On the basis of this information, more exacting laboratory testing, and ultimately more appropriate and timely treatment regimens, can be developed.

    PMID: 11686881 [PubMed - indexed for MEDLINE]

    PMCID: 2002067

    Supplemental Content

    Click here to read Click here to read

    Patient drug information